OQRO

Feed News

Explore

Insider trades Fund moves Congressional trades Federal contracts Screener

Yours

Watchlist Alerts Saved Ask Claude or ChatGPT

Create a free account Sign in

OQRO

Search/

Loading…

285 GILD shares were withheld to cover taxes or exercise cost (Officer) | OQRO

Home
Insider trades
Gilead Sciences
285 GILD shares were withheld to cover taxes or exercise cost (Officer

Insider trades

Insider trade

285 GILD shares were withheld to cover taxes or exercise cost (Officer)

Traded Sep 10, 2026 · Filed Sep 11, 2026

GILGilead SciencesGILD

285
Shares · @ $144.81

Why it stands out

Routine share withholding; mechanical by default.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Sep 10, 2026
Reporting period: Not applicable
Filed with the SEC: Sep 11, 2026

OfficerTax withholding

Context

Classification

tax withholding

Code F — shares delivered to pay exercise price or tax liability

Planned / mechanical clue

Tax mechanics (code F)

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0002110603-26-000013

Ask Claude or ChatGPT about these filings. Connect OQRO in a minute, then ask things like “which insiders bought this week?”

Filed / recorded

Sep 11, 2026, 10:28 PM UTC

Added to OQRO

Oct 2, 2026, 12:27 PM UTC

Parser

form4-xml-v1

Data quality

Verified: identifiers matched exactly

Issuer

GILEAD SCIENCES, INC.

Issuer CIK

882095

Ticker

GILD

Reporting person

Wettan Keeley M Cain

Relationship

Officer

Officer title

EVP Gen Counsel, Legal & Comp

Security

Common Stock

Table

Non-derivative (Table I)

Transaction date

Sep 10, 2026

Transaction code

Shares / units

285

Price per share

$144.81

Acquired / disposed

Disposed (D)

Shares owned after

8,759

Ownership form

Direct

Amendment

Around the same time

Daniel Patrick O'day (Chairman & CEO) sold ~$1.77M of Gilead Sciences

Scheduled in advanceFiled 4d ago

Daniel Patrick O'day (Chairman & CEO) sold ~$446K of Gilead Sciences

Scheduled in advanceFiled 4d ago

Erin BurkhartSVP, Controllership

Filed 2w ago

2,223Shares

Traded Sep 22 · filed 1 day later

Derivative exercise or conversion — not an open-market buy.

More Official record